On a private clinic website, “access scheme” may describe that provider’s own reduced-fee or membership offer. It is not an NHS Patient Access Scheme, an NHS prescribing route, a government benefit or the MHRA Early Access to Medicines Scheme. The name alone does not establish which costs are lower, who can join or how long the terms last, so check the current written offer before paying.
Key takeaways
- Access schemes are provider-defined; there is no standard medical cannabis access-plan contract.
- Eligibility, joining fees, review fees, prescription charges and medicine costs can be treated differently.
- A low entry price does not show the likely annual cost.
- The clinical assessment should not become less thorough because a patient uses a reduced-fee plan.
- Check the clinic’s regulator entry and the initiating specialist separately from the price offer.
- If cost may interrupt prescribed treatment, speak to the clinic or prescriber before making changes.
What the written terms need to show
Do not assume that the word “access” includes a particular discount or patient group. Ask the provider to identify every included and excluded fee, medicine or pharmacy cost; any evidence required; the duration; and what happens if the terms change. Current written terms are more useful than an old comparison table or forum post.
The phrase can also be confused with research registries, product-price arrangements or the government’s Early Access to Medicines Scheme. Those are different things. Ask the clinic to identify exactly what it is offering and whether participation involves research questionnaires, a subscription, a minimum term or a restricted pharmacy or formulary.
An Advertising Standards Authority ruling published in January 2026 illustrates why the small print matters. It recorded that one provider’s named Access plan was restricted to students, veterans or people receiving benefits, while other plans were open more widely. The ruling concerned comparative price claims, not whether medical cannabis was clinically suitable. It should not be read as a current endorsement or a universal eligibility rule.
Questions to ask before joining
Ask for answers in writing:
- What is the joining or onboarding fee?
- Which consultation, review and repeat-prescription fees are reduced?
- Does the offer affect medicine, pharmacy or delivery costs?
- Who can join, what evidence is required and when is eligibility checked again?
- Is there a subscription, minimum term or cancellation charge?
- Can fees or included services change after joining?
- Does participation involve a registry, research questionnaires or data sharing?
- Which regulator covers the clinic and who is the initiating specialist?
- What clinical support is available between reviews?
Compare the result with the full annual cost of medical cannabis care, not only the first payment. Then use the clinic comparison framework to check regulation, specialist status, continuity and pharmacy arrangements.
Clinical care still comes first
Paying less should not alter the prescriber’s duties. GMC and NHS England guidance still require relevant records, an individual assessment, informed decision-making, specialist responsibility and appropriate monitoring. Initial unlicensed prescribing should generally receive peer review through an appropriate MDT or equivalent clinical-governance process.
An access plan cannot show that you are suitable for treatment. A checker may indicate that you may qualify, but records, previous treatments, risk factors and specialist assessment determine the clinical decision. Be cautious if a discount is presented alongside pressure to join quickly or an implied promise of a prescription.
If you are already prescribed and costs have become difficult, contact the clinic before missing reviews, changing a medicine or stopping treatment. Ask which charges are essential, whether a different payment structure exists and what a safe continuity plan would look like. The answer may be financial, clinical or both.
Read next
- Medical cannabis costs in the UK
- Clinic fees to ask about before signing up
- How to compare medical cannabis clinics without rankings
- NHS versus private medical cannabis prescriptions
Source trail
- ASA: January 2026 ruling on medical cannabis clinic price comparisons
- GMC: Information for doctors on cannabis-based products for medicinal use
- NHS England: Cannabis-based products for medicinal use
- NHS England: Free-of-charge medicines schemes and Patient Access Schemes
- CQC: Find regulated care services in England
- MHRA: Early Access to Medicines Scheme
